Kiora Pharmaceuticals names Keith Lane executive vice president of clinical development
Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. Lane previously served as Chief Scientific Officer at Ora, Inc., an ophthalmology-focused clinical research organization, and his role will cover clinical development for the current pipeline, including KIO-301 for retinitis pigmentosa.
Key points
- Appointment effective September 8, 2026, under an offer letter dated June 22, 2026
- Compensation includes a $350,000 annual base salary, a $75,000 sign-on bonus, and a performance bonus with a target of up to 35% of base salary
- Option to purchase up to 55,000 shares, subject to Compensation Committee approval, with one-third vesting after one year and the rest in monthly installments over two years
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.